Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

NCT03085095 is registered in ClinicalTrials.gov with Myovant Sciences GmbH as lead sponsor.

NCT NCT03085095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03085095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
Lead sponsor
Myovant Sciences GmbH
Phase
Phase 3
Overall status
Completed
Start date
April 18, 2017
Completion date
November 26, 2021
Enrollment
1,134 (actual)
Sites
162

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer